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ethinking the
orbidity of Peripheral
rterial Disease and the
Normal” Ankle-Brachial Index*
eather L. Gornik, MD, MHS
leveland, Ohio
eripheral arterial disease (PAD) is a common condition,
stimated to affect 15% of the U.S. population above the age
f 70 years (1). The ankle-brachial index (ABI) is a simple,
oninvasive test that is used both to screen for PAD and to
stablish its diagnosis with a high degree of accuracy. In
ealthy adults without arterial occlusive disease, ankle sys-
olic pressure is typically 10 to 15 mm Hg greater than arm
brachial) systolic pressure, due to the effect of pulse wave
eflection. A truly normal ABI is above 1.10, although PAD
s generally defined as a resting ABI of 0.90 or less (2,3).
See page 1056
For decades, the ABI has been used as a basic tool of
ascular practice to quantify the severity of occlusive disease
mong patients with leg symptoms and to decide if revas-
ularization is needed. More recently, the ABI has diverged
rom this clinical use to become a marker of cardiovascular
isk. In multiple studies and a recent meta-analysis of
47,000 subjects, the presence of an abnormal ABI has
een shown to increase the risk of myocardial infarction and
eath, among other adverse outcomes, and to improve upon
he prognostic capabilities of the Framingham risk score
4–6). Given these data, professional societies have called
or the use of the ABI as a tool for cardiovascular risk
tratification and the identification of patients who require
ore aggressive risk factor modification (2,3). Indeed, it
eems that there has been a more recent focus on the link
etween PAD and heart disease in the medical literature
han on the morbidity of PAD itself.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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issen, MD, served as Guest Editor for this article.With this proliferation of high-quality epidemiologic
esearch on PAD as a coronary risk equivalent, it is possible
o overlook that PAD is a potentially disabling disease of
he legs. In this issue of the Journal, McDermott et al. (7)
emind us of the very practical origins of the ABI as a test
o evaluate leg pain. The authors extend their groundbreak-
ng work on functional decline and PAD to investigate the
ssociation of borderline and low normal ABI values with
rogressive functional impairment (7).
In the WALCS (Walking and Leg Circulation Study),
atients with and without PAD were identified from
ascular laboratories and ambulatory care practice and were
ollowed up for 5 years with annual ABI measurement,
unctional assessment, and a questionnaire for mobility loss.
obility impairment was defined as the self-reported loss of
he ability to walk one-quarter of a mile or navigate a single
ight of stairs without help or the inability to complete a
-min walk test. Patients were categorized according to the
ower ABI of the 2 limbs at baseline, including normal ABI
1.10 to 1.30), PAD (ABI 0.90), as well as borderline
AD (ABI 0.90 to 0.99) and low normal ABI (ABI 1.00 to
.09). Consistent with prior studies, subjects with ABI
0.90 were more likely to develop mobility impairment
uring the follow-up period than were subjects with normal
BI, with the greatest risk among subjects with ABI 0.50
t baseline (hazard ratio: 4.16) (8,9). Notably, subjects with
ow normal ABI and borderline PAD also had a significant
isk of mobility loss during follow-up (hazard ratios: 2.61
nd 3.07, respectively). The likely mechanism of functional
ecline among subjects with ABI 0.90 to 1.09 was progres-
ive arterial occlusive disease. During the 5 years of follow-
p, 50% of subjects with borderline PAD (ABI 0.90 to 0.99)
nd 17% of patients with low normal (1.00 to 1.09) had a
ecline in ABI value to 0.90, and the association between
obility loss and borderline and low normal ABI was
ttenuated after adjustment for disease progression. Quality
f life data from this cohort would be of interest, although
hey are not reported here. Nonetheless, these are important
ew data establishing the potential for progressive func-
ional impairment and disability among patients previously
lassified as “normal” in the noninvasive vascular laboratory.
This study serves as a reminder of the morbidity associ-
ted with PAD. While the classic symptom of intermittent
laudication is reported in less than one-quarter of patients
ith PAD (8,10), even those with atypical leg symptoms or
o self-reported leg symptoms have impaired walking abil-
ties (8). Peripheral arterial disease impairs quality of life and
as even been associated with symptoms of depression
11–13).
What therapies are available to patients with leg symp-
oms and/or functional impairment due to PAD? Although
upervised exercise rehabilitation is the single most effective
reatment for claudication, it is not available to most
atients because of absent reimbursement for such programs
y third-party payers (14). Home-based and partially super-
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Morbidity of PAD and the Ankle-Brachial Index March 24, 2009:1063–4ised exercise training programs require further develop-
ent and study. It has been more than a decade since the
ood and Drug Administration has approved a new drug for
he treatment of claudication (namely, cilostazol in 1999),
nd there are only 2 drugs available to patients. Despite the
ramatic upsurge in the performance of catheter-based
evascularization procedures to treat leg symptoms related to
AD, the effectiveness and sustained benefit of this strategy
re unproven. Aside from supervised exercise, there are no
roven therapies to prevent or reverse functional decline and
obility loss among patients who have atypical leg symp-
oms, the majority of the PAD population (15). The
dentification of effective therapies to improve function and
uality of life and to prevent disability among patients with
AD, across the entire spectrum of disease, is an area of
reat unmet medical need.
Finally, McDermott et al. (7) draw attention to the
volving concept of the “normal” ABI. Although an ABI
ut-point of 0.90 is used in most vascular laboratories for the
iagnosis of PAD and is the diagnostic criterion of the 2
ajor PAD practice guidelines, an ABI of 1.10 is not
ormal (2,3). A patient with low normal or borderline ABI
t rest should undergo repeat ABI measurement after
readmill (or other) exercise, a procedure that will result in
significant fall in ABI in up to one-half of patients (16,17).
f exercise is not possible, these patients should be identified
s having subclinical PAD and followed up for disease
rogression.
Low normal and borderline ABI values increase cardio-
ascular risk and the likelihood of subclinical atherosclerosis
n other vascular beds (4,5,18), and a normal ABI at rest
hat falls with exercise predicts adverse outcome (17). Now
t has been established that an ABI of 1.10 is associated
ith progressive functional decline and mobility loss (7).
he ABI is a stalwart tool, but there is a need for updated
onsensus guidelines as to its optimal interpretation in
ascular practice.
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